MotieGhader, HabibTabrizi-Nezhadi, ParinazAbad Paskeh, Mahshid DeldarBaradaran, BehzadMokhtarzadeh, AhadHashemi, MehrdadLanjanian, HosseinJazayeri, Seyed MehdiMaleki, MasoudKhodadadi, EhsanNematzadeh, SajjadMaghsoudloo, MazaherMasoudi-Nejad, AliKiani, Farzad2022-06-162022-06-162022MotieGhader H, Tabrizi-Nezhadi P, Deldar Abad Paskeh M, Baradaran B, Mokhtarzadeh A, Hashemi M, Lanjanian H, Jazayeri SM, Maleki M, Khodadadi E, Nematzadeh S, Kiani F, Maghsoudloo M, Masoudi-Nejad A. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis. Sci Rep. 2022 Jun 8;12(1):9417. doi: 10.1038/s41598-022-13719-8. PMID: 35676421; PMCID: PMC9177601.2045-2322http://doi.org/10.1038/s41598-022-13719-8https://hdl.handle.net/20.500.12713/2913Lung cancer is the most common cancer in men and women. This cancer is divided into two main types, namely non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Around 85 to 90 percent of lung cancers are NSCLC. Repositioning potent candidate drugs in NSCLC treatment is one of the important topics in cancer studies. Drug repositioning (DR) or drug repurposing is a method for identifying new therapeutic uses of existing drugs. The current study applies a computational drug repositioning method to identify candidate drugs to treat NSCLC patients. To this end, at frst, the transcriptomics profle of NSCLC and healthy (control) samples was obtained from the GEO database with the accession number GSE21933. Then, the gene co-expression network was reconstructed for NSCLC samples using the WGCNA, and two signifcant purple and magenta gene modules were extracted. Next, a list of transcription factor genes that regulate purple and magenta modules’ genes was extracted from the TRRUST V2.0 online database, and the TF–TG (transcription factors–target genes) network was drawn. Afterward, a list of drugs targeting TF–TG genes was obtained from the DGIdb V4.0 database, and two drug–gene interaction networks, including drug-TG and drug-TF, were drawn. After analyzing gene co-expression TF–TG, and drug–gene interaction networks, 16 drugs were selected as potent candidates for NSCLC treatment. Out of 16 selected drugs, nine drugs, namely Methotrexate, Olanzapine, Haloperidol, Fluorouracil, Nifedipine, Paclitaxel, Verapamil, Dexamethasone, and Docetaxel, were chosen from the drug-TG sub-network. In addition, nine drugs, including Cisplatin, Daunorubicin, Dexamethasone, Methotrexate, Hydrocortisone, Doxorubicin, Azacitidine, Vorinostat, and Doxorubicin Hydrochloride, were selected from the drug-TF sub-network. Methotrexate and Dexamethasone are common in drug-TG and drug-TF sub-networks. In conclusion, this study proposed 16 drugs as potent candidates for NSCLC treatment through analyzing gene co-expression, TF–TG, and drug–gene interaction networks.eninfo:eu-repo/semantics/openAccessArticle121WOS:0008090835000752-s2.0-85131645660Q210.1038/s41598-022-13719-8Q1